Medical/Pharmaceuticals
Alar Announced Buprenorphine Injectable, ALA-1000, Demonstrated Long-Term Efficacy and Favorable Safety Profile in Canine Osteoarthritis Pain Management
* A study in client-owned dogs with osteoarthritis demonstrated that a single injection of ALA-1000 effectively mitigates pain and improves functional mobility, with a sustained drug release profile for at least 1 month. The study also confirmed a favorable safety profile with repeated use, par...
2026-03-16 20:00
4357
Celltrion announces U.S. availability of AVTOZMA® (tocilizumab-anoh) subcutaneous (SC) formulation
* AVTOZMA® (tocilizumab-anoh) is among the first wave of tocilizumab biosimilars with both intravenous (IV) and subcutaneous (SC) formulations approved and commercially available inthe United States * The launch of AVTOZMA SC further diversifies Celltrion's immunology portfolio beyond TNF-alp...
2026-03-16 20:00
6085
GenScript Biotech Corp Reports Strong FY2025 Results as Integrated Platform Strategy and Global Execution Drive High-Quality Growth
Group Performance * Revenue: US$959.5 million, +61.4% year-on-year * Gross profit: US$553.2 million, +103.3% year-on-year * Adjusted net profit: US$230.3 million, +285.0% year-on-year Business Units' Performance * GenScript Life Science Group (LSG): US$522.1 million, +14.8% year-on-year ...
2026-03-16 18:54
6753
Everest Medicines to Announce 2025 Full-Year Financial Results on March 26, 2026 and Hold Online Earnings Call
SHANGHAI, March 16, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will report its financial re...
2026-03-16 17:58
7559
KLN Named Full-line Distributor for APT Medical's Coronary Intervention Products in Hong Kong
HONG KONG, March 16, 2026 /PRNewswire/ -- KLN Logistics Group Limited ('KLN'; Stock Code 0636.HK) is pleased to announce that its healthcare subsidiary, KLN Medical Limited ('KLN Medical'), is now the full-line distributor for APT Medical Inc.'s ('APT Medical'; Stock Code 688617.SH) coronary inte...
2026-03-16 12:05
4614
Akeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance
HONG KONG, March 15, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced today that its proprietary first-in-class trispecific antibody, AK150 (ILT2/ILT4/CSF1R), has received Investigational New Drug (IND) clearance from the National Medical Products Administration (N...
2026-03-16 10:05
6961
Trial to test mild hyperbaric oxygen therapy during active treatment for aggressive brain cancer
LISMORE, Australia, March 15, 2026 /PRNewswire/ -- Australian researchers from Southern Cross University (SCU) and the Melbourne Integrative Oncology Group (MIOG) will launch a clinical study investigating whether hyperbaric oxygen therapy (HBOT) can safely support patients undergoing treatment f...
2026-03-16 09:43
3882
SUBANG JAYA MEDICAL CENTRE RANKED AMONG THE WORLD'S TOP 250 HOSPITALS AND TOP 10 REGIONALLY IN NEWSWEEK'S 2026 RANKING
KUALA LUMPUR, Malaysia, March 16, 2026 /PRNewswire/ -- Subang Jaya Medical Centre (SJMC) has been named among the Top 250 hospitals globally and top 10 regionally in Newsweek's World's Best Hospitals 2026, placing it among a select group of leading hospitals worldwide. The recognition highlights ...
2026-03-16 09:00
5119
Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate
MELBOURNE, Australia and INDIANAPOLIS, March 16, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces the resubmission of a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-Px, (Pixclara®[1], Floret...
2026-03-16 05:26
5512
Spring Into Healthy Breathing: Varon Offers Tips for Travel and Wellness with Oxygen Support
NEW YORK, March 15, 2026 /PRNewswire/ -- Spring is here, bringing warmer
weather, outdoor adventures, and family travel. For individuals who rely on
supplemental oxygen, enjoying the season safely requires preparation and the
right equipment. VARON
2026-03-15 14:03
5221
Vimgreen's Novel A2AR Antagonist Receives CDE IND Approval for NASH/MASH Therapy
HANGZHOU, China, March 14, 2026 /PRNewswire/ -- Vimgreen Pharmaceuticals, a leading innovator in adenosine signaling modulation, today announced the approval of its Investigational New Drug (IND) application for VG081821 in non‑alcoholic steatohepatitis (NASH), increasingly referred to as metabol...
2026-03-14 12:33
4663
Biophytis-LynxKite Alliance Expands to Turbocharge AI-driven drug discovery for next generation longevity therapeutics
* Biophytis and LynxKite launch new modalities beyond MASSIVE: AI-driven drug discovery for next-generation longevity therapies * This partnership will generate revenue through: * A computational longevity platform, including unique curated datasets and accelerated computation methods releva...
2026-03-13 23:40
7900
Insilico Medicine to Announce 2025 Financial Results on March 30, 2026
CAMBRIDGE, Mass., March 13, 2026 /PRNewswire/ -- Insilico Medicine (HKEX: 3696.HK, "Insilico" or the "Company"), a clinical-stage biotechnology company powered by generative artificial intelligence for drug discovery and development, today announced that it will report its financial results for t...
2026-03-13 21:59
9756
CityUHK researchers unveil the mystery of "Asian Flush" mechanism, pioneering new directions in precision treatment for heart attacks
HONG KONG, March 13, 2026 /PRNewswire/ -- Approximately 40% of the East Asian population suffers from alcohol intolerance, commonly known as "Asian Flush Syndrome". This ALDH2 genetic mutation is more than just a metabolic defect; it conceals a deadly cardiovascular risk. While the medical commu...
2026-03-13 21:30
6411
BioDlink Named "Emerging CDMO of the Year" at the 2026 Asia-Pacific Biopharma Excellence Awards
* BioDlink has been named "Emerging CDMO of the Year" for its innovation in complex biologics and ADC development. * The award recognizes its proprietary technology platforms, scalable manufacturing, and a proven quality system with over 100 audits completed. SUZHOU,China, March 13, 2026 /PRN...
2026-03-13 21:00
7680
Unixell Biotech receives IND clearance by FDA for its Allogeneic iPSC-Derived cell therapy, UX-GIP001, for focal Epilepsy
SHANGHAI, March 13, 2026 /PRNewswire/ -- On March 12, Unixell Biotech achieved a significant milestone as UX-GIP001, its iPSC-derived allogeneic cell therapy targeting focal epilepsy, secured Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA). This breakthro...
2026-03-13 20:06
4441
POMDOCTOR LIMITED Announces Strategic Upgrade, Focusing on "AI + Medical-Grade Smart Wearables" to Build a New Ecosystem for Full-Cycle Chronic Disease Management
GUANGZHOU, China, March 13, 2026 /PRNewswire/ -- Pomdoctor Limited ("Pomdoctor" or the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases inChina, today announced a strategic upgrade centered on the core track of "artificial intelligence ("AI") + medical-gra...
2026-03-13 20:00
6663
Esaote at EAU 2026: Introducing Exclusive PAM Technology to Advance Precision in Urological Imaging
The technology is available on the new MyLab™E85 GTS Edition that will be showcased together with the brand new MyLab™C30 GTS ultrasound system at the Esaote booth LONDON, March 13, 2026 /PRNewswire/ -- Esaote Group, a leading Italian innovator in medical imaging - ultrasound, dedicated magnetic...
2026-03-13 19:00
4660
Everest Medicines' Licensing Partner NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study
* VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 inhibitor * Topline Phase 2a data show VIS-101 provides rapid, robust and durable treatment responses in wet AMD * VIS-101 demonstrated mean BVCA improvements of >10 ETDRS let...
2026-03-13 18:05
7407
Aphranel Named to Forbes China Beauty 100 List
SHANGHAI, March 12, 2026 /PRNewswire/ -- Aphranel, a China-origin regenerative medical aesthetics brand under the companySHANGHAI MOYANG BIOTECHNOLOGY, has been named to the Third Forbes China Beauty 100 list, published byForbes China, which recognizes brands in China's beauty and medical aesthet...
2026-03-13 11:23
4748
Week's Top Stories
Most Reposted
Agoda and Singapore Tourism Board Expand Partnership to Boost Demand and Tech Transformation in Tourism
[Picked up by 313 media titles]
2026-08-14 10:00
Agoda Launches AI-Powered Room Grid Bot to Help Travelers Decide Which Room to Book
[Picked up by 313 media titles]
2026-08-13 12:00
PARKROYAL COLLECTION Marina Bay, Singapore Named Among Singapore's Top 10 Hotels by Travel + Leisure and Featured on 50 Best Discovery
[Picked up by 312 media titles]
2026-08-14 12:27
GCash Parent Mynt Cited as Sole Philippine Firm in World's Top Fintech Companies List
[Picked up by 296 media titles]
2026-08-12 16:02
Appier Delivers Record-High Revenue, Profitability and Core Free Cash Flow
[Picked up by 295 media titles]
2026-08-13 23:42Most Read
AMTD IDEA's Receipt of NYSE Letter Regarding ADS Trading Price's Below Compliance Standards
2026-08-08 04:01
17497
China Yuchai International Announces Unaudited 2026 First Half-Year Financial Results
2026-08-07 18:00
17253
